Clinical Trial Update: Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating AC2993 with or without immunosuppression on beta cell function in Type 1 diabetes; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• AC2993 (AC2993)

Snippet

Sponsor: AstraZeneca | Conditions: Diabetes Mellitus | Phase 2 | Status: COMPLETED